(ovary, mesothelium), and thyroid transcription factor-1 (lung, thyroid).
Selection of the appropriate subset of these antibodies can be most helpful in clinical situations where there is a limited set of possible primary sites (e.g.,
I. Introduction
Immunohistochemical analysis has become an increasingly important tool for analysis of tumors, and has traditionally been employed to help pathologists determine the nature of tumors in which analyses of hematoxylin and eosin stained slides prove insufficient to render a definitive diagnosis.
The recent availability of monoclonal antibodies with defined specificities to cytokeratin subsets and organ-related markers has now made it possible to provide critical information regarding the probable site of origin of carcinomas presenting at metastatic sites, usually in the context of lymph node, liver, or brain metastases.
It is impossible
to recommend a single 'screening panel' of antibodies to determine the primary site of such carcinomas, given the fact that this panel will be highly dependent upon the clinical setting, and therefore differential diagnosis, of a particular case. Tumors that would be considered in the differential diagnosis of an axillary lymph node in a 55 year old female would be different than those entertained in periaortic lymph nodes in a 75 year old male. Markers such as prostatic specific antigen (PSA) might play a minor role in the analysis of the former but not the latter (although PSA has been demonstrated to be a breast carcinoma-related antigen [18] .) The complexity of the situation can be simplified by identifying the different major approaches that can help identify the primary site of a carcinoma presenting at a metastatic site. Because cytokeratin expression is the sine qua non of epithelial differentiation, i.e., carcinomas, detection of cytokeratins plays an important role in the analysis of these tumors.
II. Cytokeratins
Cytokeratins, comprising a subfamily of more than 20 members, are the most complex member of the inter- [2, 21] . More recent studies [19, 34] have demonstrated that examination of coordinate expression of these two cytokeratins can provide more information regarding carcinoma type than examination of these individual cytokeratins alone. In our recent study [34] , a total of 384 cases of carcinomas primary to various organs, as well as 16 cases of malignant mesothelioma, were evaluated using commercially available monoclonal antibodies. The subset of tumors strongly expressing both CK 7 and CK 20 included virtually all bladder transitional cell carcinomas and the majority of pancreatic adenocarcinomas; the tumors negative for both CK 7 and CK 20 were largely restricted to hepatocellular, prostate and renal cell carcinomas in addition to squamous cell and neuroendocrine carcinomas of lung. The CK 7-/CK 20+ immunophenotype, on the other hand, was highly characteristic of adenocarcinomas of colorectal origin, whereas CK 7+/CK 20-immunophenotype was typically seen in the vast majority of carcinomas arising from other sites, including ovary, endometrium, breast, and lung, as well as malignant mesothelioma.
Gastric carcinomas were the most heterogeneous subgroup with respect to their CK 7/CK 20 immunophenotype.
In the subset of mucinous tumors, striking immunophenotypic differences were noted among those primary to the breast (CK 7+/CK 20-), gastrointestinal tract (CK 7-/CK 20+), and ovary (CK 7+/CK 20+).
In Gown of metastatic tumors. Unlike the intermediate filament proteins, CEA expression may be directly proportional to the degree of cellular differentiation, i.e., more poorlydifferentiated tumors of a given cell type tend to express less CEA than well-differentiated tumors with the same type. CEA is actually a family of high molecular weight glycoproteins (all of which are, in turn, part of a "superfamily" of proteins which include the immunoglobulins, certain cell adhesion molecules, etc.) that have recently been assigned the designation CD66 (with the variants CD66a, CD66b, etc.; the older nomenclature 'CEA' is equivalent to CD66e [16, 35] .) The CEA family includes "true" CEA , along with "nonspecific cross reacting antigen (NCA), biliary glycoprotein (BGP), and others. It has been well-established that antisera prepared by conventional immunization with CEA contain several antibodies of different specificities, i.e., such antisera cross react with NCA and BGP. Most anti-CEA polyclonal antibodies Table 1 . Summary of 'CEA' expression in carcinomas Table  2 . Table  3 . Table  4 .
and some monoclonal anti-CEA antibodies react with both CEA and NCA, and hence will identify polymorphonuclear leukocytes in tissue sections. This can have positive as well as negative implications: while these serve as good "built-in" controls, necrotic tumors of any type will often manifest CEA positivity as a consequence of this NCA cross reactivity. New antibodies, such as the II-7 clone, do not show this cross reactivity and can be used in place of, or in conjunction with, the cross-reacting clones. Table 1 summarizes the expression of CEA within different types of carcinomas.
Vimentin co-expression While co-expression of cytokeratin (the "signature" intermediate filament of carcinomas) and vimentin (the intermediate filament generally associated with mesenchymal cells) is the norm under in vitro conditions, co-expression of vimentin with cytokeratin in vivo is a characteristic of only a limited subset of carcinomas (e.g., renal cell carcinoma, endometrial carcinoma, etc.). One important overriding rule is important to remember: any spindle cell carcinoma (indeed, any spindle tumor of any kind) will co-express vimentin. This is summarized in Table 2 .
Tumors in the column at the right may co-express vimentin, albeit rarely. In fact, in the case of breast carcinoma, co-expression of vimentin may be a marker of adverse outcome [11] .
Antibodies to tissue-specific proteins
There are relatively few tissue-specific markers that can be exploited in the analysis of metastatic carcinomas. However, by far the most useful are the prostatic markers, PSA (prostatic specific antigen) and PAP (prostatic acid phosphatase).
The former is more specific than the latter, as a subset of hindgut carcinoid tumors can also express PAP [3] . When used in combination, these two markers will identify greater than 95% of all metastatic prostatic adenocarcinomas.
Other tissuespecific markers include antibodies to thyroglobulin (a thyroid-specific marker) and the gross cystic disease fluid protein-15, a breast/sweat/salivary gland marker. The latter, while characterized in the literature as a good marker of metastatic breast cancer, is, in our experience, positive in only a minority of metastatic breast cancers, especially the infiltrating ductal type, and among poorly differentiated subtypes. We have recently demonstrated that mesothelin is a highly sensitive marker of serous papillary ovarian carcinoma, and that antibodies to surfactant apoA protein identify greater than 65% of pulmonary non-small cell carcinomas. Recently published studies have also pointed to the great potential value of the nuclear protein, thyroid transcription factor-1 (TTF-1), as a powerful marker of lung and thyroid carcinomas [4] . The various tissue-specific markers are summarized in the Table 3 , and graded according to their sensitivity and specificity.
Antibodies to estrogen and progesterone receptor proteins Antibodies to estrogen and progesterone receptors can play an important, albeit limited role, in the identification of the primary site of carcinomas presenting at a metastatic site. It is important to note, however, that these antibodies can in no way be considered a specific marker of metastatic breast carcinoma, despite the large numbers of studies performed at many institutions specifically (and exclusively) for this marker. First, it is important to appreciate the wide spectrum of tumors that have the ability to express estrogen and/or progesterone receptors. The major utility of antibodies to ER and PR arises in the recognition that certain tumors that may be in the differential diagnosis never (or almost never) express ER and/or PR. These are summarized in Table 4 .
VI.
The Concept of 'Contextual Specificity'
Some markers have greater value in restricted clinical situations than in a hypothetical situation in which all primary sites are considered. Thus, if a patient with a history of breast cancer presents with a pulmonary nodule, the presence of ER expression can point rather unequivocally to the diagnosis of metastatic breast cancer and rule out the diagnosis of a second lung nonsmall cell carcinoma [9, 27] . The use of many of the markers outlined above must be considered in this context. Tables 5-7 exemplify this selective use of markers.
VII.
